Allarity Stock Price, News & Analysis

Allarity Therapeutics has appointed James G. Cullem, J.D., as interim CEO and Joan Y. Brown, CPA, as interim CFO, following the resignation of former CEO Steve R. Carchedi and CFO Jens Knudsen. The leadership transition aims to prepare the company for future growth. Cullem, with over 20 years in life sciences, has been with Allarity since 2014, focusing on the acquisition of key oncology assets. Brown brings extensive financial reporting experience, contributing to Allarity's Nasdaq listing. The board anticipates naming permanent executives in the first half of 2023.

Allarity Therapeutics has announced the appointment of Dr. Roberto Pili to its Scientific Advisory Board. With extensive expertise in renal cancers and personalized medicine, Dr. Pili will contribute to advancing Allarity's clinical programs. The company specializes in oncology therapeutics and uses its proprietary Drug Response Predictor (DRP) companion diagnostics to enhance treatment efficacy. Dr. Pili's experience includes conducting clinical trials and publishing over 200 peer-reviewed articles. Allarity aims to improve cancer treatment outcomes through innovative therapies guided by individualized patient diagnostics.

Allarity Therapeutics reported their Q1 2022 financial results, showing a net loss of $3.1 million, unchanged from Q1 2021. Their cash reserves declined to $14.5 million from $19.6 million in the previous quarter. R&D expenses remained flat at $1.3 million year over year, while G&A expenses rose significantly to $3.0 million from $1.2 million. The company recorded a notable $14.0 million impairment of intangible assets, compared to none in the prior year. Allarity continues to advance its pipeline for personalized cancer therapies using its DRP® companion diagnostics.

Allarity Therapeutics (NASDAQ: ALLR) corrected a typographical error in its press release dated May 16, 2022. The company stated that the debt cancellation amount was incorrectly reported as "$971 million" instead of "$971 thousand." This debt cancellation exempts Allarity from future financial obligations related to the LiPlaCis® program, allowing for potential milestone payments of up to $3.5 million. The company is focused on developing personalized cancer treatments using its Drug Response Predictor (DRP®) companion diagnostic technology.

Allarity Therapeutics reported financial results for Q4 and full year 2021, highlighting significant achievements including a successful Nasdaq listing under symbol ALLR and a record investment of $20 million. The company advanced its cancer therapeutics pipeline and announced a forbearance agreement to address compliance issues with Nasdaq. Notably, R&D expenses surged to $14.2 million, leading to a net loss of $26.6 million for 2021. Positive developments include a Type C meeting with the FDA on dovitinib and milestone payments from partnerships. Cash reserves increased to $19.6 million.

Allarity Therapeutics, Inc. (Nasdaq: ALLR) announced it is not in compliance with Nasdaq Listing Rule 5250(c)(1), due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The notification does not immediately affect the listing of the Company's common stock. Allarity has 60 days to submit a compliance plan, with a potential extension of up to 180 days if accepted. The Company aims to file its Form 10-K by June 19, 2022, to eliminate the need for a formal compliance plan.

Allarity Therapeutics has requested a Type C meeting with the FDA to discuss the next steps for dovitinib, after the agency issued Refusal to File letters for its NDA and PMA applications. The Company aims to clarify the requirements for resubmission and anticipates a new clinical trial may be necessary. Allarity plans to provide updates on the meeting outcomes and further advancements for dovitinib and its DRP-Dovitinib companion diagnostic by the end of Q3 2022. CEO Steve Carchedi remains confident in dovitinib's potential as a treatment for cancer patients.

Allarity Therapeutics, Inc. announced that the FDA issued Refusal to File letters for their new drug application (NDA) for dovitinib and the companion diagnostic DRP®-Dovitinib. The FDA cited insufficient clinical trial data to conclude efficacy for the metastatic renal cell carcinoma treatment. Allarity plans to seek FDA guidance and likely conduct a new clinical trial to address the issues raised. Despite this setback, Allarity's CEO remains confident in dovitinib's potential as a treatment option.

Allarity Therapeutics (Nasdaq: ALLR) has entered into licensing agreements with Oncoheroes Biosciences for the development of dovitinib and stenoparib in pediatric cancers. Oncoheroes will fund and advance clinical trials, while Allarity will provide support and supply drug inventory. Allarity submitted a new drug application (NDA) for dovitinib in renal cell carcinoma (RCC), alongside the Dovitinib-DRP® companion diagnostic. The company is also evaluating stenoparib for advanced ovarian cancer. Financial terms of the agreements remain undisclosed.